PCA
TVRD

Private Capital Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Private Capital Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-6,857
Closed -$4.16M – 112
2015
Q4 		$4.16M Buy
+6,857
New +$3.76M 1.8% 19
2015
Q3 		– Sell
-656
Closed -$287K – 127
2015
Q2 		$287K Buy
+656
New +$254K 0.09% 126

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Private Capital Advisors's TVRD Position: Q1 2016 in Review

Private Capital Advisors sold out of Tvardi Therapeutics (TVRD) in Q1 2016, closing a stake of 6,857 shares — an estimated $4.16M sold.

Private Capital Advisors first reported a position in TVRD in Q2 2015 and held it in 2 quarters. The position peaked at $4.16M in Q4 2015. 93 funds tracked by Wall St. Rank hold TVRD as of Q1 2016.

  • Private Capital Advisors reported no remaining Tvardi Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Private Capital Advisors sold 6,857 Tvardi Therapeutics shares in Q1 2016, an estimated $4.16M.
  • Private Capital Advisors first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 2 quarters.
  • Private Capital Advisors's Tvardi Therapeutics position peaked at $4.16M in Q4 2015.
  • 93 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2016.

Based on Private Capital Advisors's 13F filing for Q1 2016, filed 26 Apr 2016.